Xu Lufan, Ma Xinxin, Yang Yang, Ding Zhiqiang, Luo Yi
Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Nantong Tumor Hospital, Tumor Hospital Affiliated to Nantong University, Nantong, China.
Front Immunol. 2025 Mar 24;16:1543114. doi: 10.3389/fimmu.2025.1543114. eCollection 2025.
The advent of immunotherapy has transformed the therapeutic landscape for inoperable, locally advanced Non-Small cell lung cancer (NSCLC), particularly for lung squamous cell carcinoma (LUSC) with a predominance of negative driver genes. Based on the results of clinical trials such as KEYNOTE-042 and KEYNOTE-407, PD-1/PD-L1 inhibitors are now recognized as the standard of care for first-line or second-line treatment in many countries. Among the 17 immune checkpoint inhibitors sanctioned in China, tislelizumab, a domestically developed PD-1 inhibitor, enjoys broad application. Here, we present a case of a patient with LUSC who attained complete remission by cyst formation with the combination of tislelizumab and chemotherapy. Despite the absence of expression data for this patient, imaging studies revealed a reduction in the primary lesion size and the emergence of an uncommon cystic alteration post-treatment with sequential immunochemotherapy and tislelizumab monotherapy. As per the most recent follow-up, the lesion has vanished entirely. This outcome holds significant implications for the treatment of driver gene-negative LUSC by tislelizumab.
免疫疗法的出现改变了不可切除的局部晚期非小细胞肺癌（NSCLC）的治疗格局，尤其是对于驱动基因阴性占主导的肺鳞状细胞癌（LUSC）。基于KEYNOTE-042和KEYNOTE-407等临床试验结果，PD-1/PD-L1抑制剂目前在许多国家被公认为一线或二线治疗的标准疗法。在中国获批的17种免疫检查点抑制剂中，国产PD-1抑制剂替雷利珠单抗得到了广泛应用。在此，我们报告1例LUSC患者，该患者通过替雷利珠单抗与化疗联合治疗形成囊肿而实现完全缓解。尽管该患者没有表达数据，但影像学研究显示，序贯免疫化疗和替雷利珠单抗单药治疗后，原发灶大小缩小，出现了罕见的囊性改变。根据最新随访结果，病灶已完全消失。这一结果对替雷利珠单抗治疗驱动基因阴性的LUSC具有重要意义。
